ISIN | LU1540961247 |
---|---|
Valor Number | 35006956 |
Bloomberg Global ID | |
Fund Name | HBM UCITS (Lux) Funds-HBM Global Healthcare Fund P USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital gains, by pursuing a long/short strategy in the "healthcare" market. The goal is to generate a value trend that exceeds the performance of the SOFR (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 245.68 USD | 25.06.2025 |
---|---|---|
Previous Price * | 246.45 USD | 24.06.2025 |
52 Week High * | 293.00 USD | 16.09.2024 |
52 Week Low * | 225.43 USD | 08.04.2025 |
NAV * | 245.68 USD | 25.06.2025 |
Issue Price * | 245.68 USD | 25.06.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 16,472,256 | |
Unit/Share Assets *** | 14,284,238 | |
Trading Information SIX |
YTD Performance | -3.52% |
31.12.2024 - 25.06.2025
31.12.2024 25.06.2025 |
---|---|---|
YTD Performance (in CHF) | -14.43% |
31.12.2024 - 25.06.2025
31.12.2024 25.06.2025 |
1 month | +2.12% |
26.05.2025 - 25.06.2025
26.05.2025 25.06.2025 |
3 months | -3.60% |
25.03.2025 - 25.06.2025
25.03.2025 25.06.2025 |
6 months | -4.63% |
27.12.2024 - 25.06.2025
27.12.2024 25.06.2025 |
1 year | -9.68% |
25.06.2024 - 25.06.2025
25.06.2024 25.06.2025 |
2 years | +2.85% |
26.06.2023 - 25.06.2025
26.06.2023 25.06.2025 |
3 years | +5.93% |
29.06.2022 - 25.06.2025
29.06.2022 25.06.2025 |
5 years | +18.27% |
30.06.2020 - 25.06.2025
30.06.2020 25.06.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.60% | |
---|---|---|
AbbVie Inc | 5.45% | |
UnitedHealth Group Inc | 5.11% | |
Gilead Sciences Inc | 5.10% | |
Stryker Corp | 4.85% | |
UCB SA | 4.58% | |
Roche Holding AG | 4.28% | |
Lonza Group Ltd | 3.99% | |
Sanofi SA | 3.95% | |
The Cooper Companies Inc | 3.84% | |
Last data update | 31.03.2025 |
TER | 0.0165% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.20% |
Ongoing Charges *** | 1.81% |
SRRI ***
|
|
SRRI date *** | 31.05.2025 |